REVANCE THERAPEUTICS INC - NOTE 1.750% 2/1 Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2021 to Q1 2025

Type / Class
Debt / NOTE 1.750% 2/1
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Institutional Holders of REVANCE THERAPEUTICS INC - NOTE 1.750% 2/1 across Reporting Periods

Period Principal Value Change Price (% of par) (Median) Investors
2025 Q1 $0 $0 -$237,500,723 0
2024 Q4 $188,131,543 $237,976,348 -$7,868,518 95.74% 18
2024 Q3 $197,744,550 $176,846,616 +$6,712,325 85.44% 22
2024 Q2 $212,353,242 $139,496,291 -$15,500,337 65.6% 21
2024 Q1 $231,994,242 $202,469,009 -$23,078,977,898 72.75% 22
2023 Q4 $264,943,000 $201,238,321 +$13,097,322 75.94% 23
2023 Q3 $245,718,242 $198,931,644 -$16,150,064 80.47% 29
2023 Q2 $254,646,421 $269,088,244 -$13,759,672 105.64% 28
2023 Q1 $265,005,282 $330,401,198 +$43,557,319 123.15% 28
2022 Q4 $253,368,000 $234,923,888 -$49,050,168 92.3% 24
2022 Q3 $323,081,000 $353,201,545 +$9,517,776 108.52% 28
2022 Q2 $273,236,000 $226,785,000 +$15,533,536 81.56% 18
2022 Q1 $249,383,000 $239,572,000 -$21,994,040 94.06% 19
2021 Q4 $252,502,187 $225,617,587 -$17,407,568 88.3% 19
2021 Q3 $282,389,000 $325,197,920 +$23,117,160 114.94% 21
2021 Q2 $261,971,087 $306,514,595 +$5,146,358 116.96% 25
2021 Q1 $265,777,587 $298,923,677 +$298,923,677 112.08% 27